This 55-page PowerPoint based report gives an important update to the previous year with an expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials. Findings are based on a survey conducted with respondents from around the world that belonged to Pharma/Biotech, Government/Academic Institutions, CROs, CMOs, or other contract service providers.
The report includes:
- Study Design and Key Findings.
- Primary Concerns, which include business concerns, clinical trial concerns for decentralized clinical trials and addressing trial disruption.
- Movement Toward Decentralized Trials, including pre and post pandemic decentralized clinical trials use, future movement toward using decentralized clinical trials and cost comparison.
- Challenges Facing Decentralized Trials, which explores the biggest challenges, changes, considerations and risk deviations for decentralized clinical trials.
Scope
- The publisher's Pharma clients and prospects from the around the world participated in a seven-minute survey, which was fielded from June 29, 2022 to July 28, 2022.
- This report includes and is based around industry opinions on COVID-19's impact on clinical trials and the use of decentralized clinical trials.
Reasons to Buy
- Understand companies' primary concerns about the COVID-19 pandemic.
- Determine the impact of COVID-19 to date on clinical trials.
- Assess companies' future plans to use decentralized clinical trials.
- Track changes to clinical trial strategy and attitudes.
Table of Contents
1 Study Design
3 Primary Business and Clinical Trial Concerns
4 Movement Toward Decentralized Trials
4 Challenges Facing Decentralized Trials
